ANI Pharmaceuticals has completed its acquisition of US niche generics firm Novitium Pharma, which was announced in March this year. ANI expects the acquisition to enhance the scale of its contract development and manufacturing organization business and US manufacturing capacity, gaining nine of Novitium’s CDMO customers through the acquisition alongside access to its 50,000 sq ft manufacturing facility in East Windsor, New Jersey.
The deal is also expected to bolster ANI’s niche research and development pipeline. Novitium has at least 20 launches planned...
